Mario Risi, Giacomo Greco, Stefano Masciocchi, Eleonora Rigoni, Elena Colombo, Pietro Businaro, Silvia Scaranzin, Chiara Morandi, Alvino Bisecco, Paola Bini, Luca Diamanti, Antonio Gallo, Diego Franciotta, Matteo Gastaldi
BACKGROUND: Live cell-based assay (LCBA) is the gold standard for MOG-IgG detection, and fixed CBA (FCBA) is a widely used commercial alternative. Recent criteria attributed a diagnostic value to MOG-IgG titration with both LCBA and FCBA, with low-titre samples requiring additional supporting features for MOGAD diagnosis. However, FCBA titration is not validated. We aimed to assess the impact of the criteria-based MOG-IgG testing in MOGAD diagnosis. METHODS: Thirty-eight serum samples of LCBA MOG-IgG1-positive MOGAD patients were titred on MOG-IgG LCBA and FCBA, and the presence of supporting features for MOGAD assessed...
January 27, 2024: Journal of Neurology